Dr. John Cush RheumNow
3 years ago
IL-2 receptor (sCD25) levels as a biomarker of RA-ILD? Study of 294 RA pts (56 w/ ILD) & 58 healthy controls (HCs) (ILD confirmed by HRCT). sCD25 sensitivity 51% & specificity 77%,; it elevated in RA-ILD subtypes (UIP, NSIP); but didnt correlate w/ HRCT https://t.co/1gJ635tu8a https://t.co/aYamfJwJi2
PMR might be one of the most rewarding diagnoses to make in real practice: the patient comes to you in severe debilitating pain, and you prescribe steroids, giving them their lives back! As much as this impressive response makes your intervention appear almost magical, there is the often-forgotten story about the implications of such a diagnosis and treatment on patients' daily lives.
Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.
Dr. John Cush RheumNow
3 years ago
JAKne? Systematic review &meta-analysis (25 studies, 10 839 pts), JAK inhibitor use was associated with an elevated odds of acne (OR 3-5 for UPA, TOFA, BARI, Deucra; but higher for abrocitinib (OR 13.5). Seen in Derm pts but hardly at all in Rheum pts https://t.co/XdHmARnxpu https://t.co/N7Bm5GIgjd
Dr. John Cush RheumNow
3 years ago
RHEUM Survey: In Newly Dx #PMR patients, How many do you do imaging for GCA vascular involvement?
Dr. John Cush RheumNow
3 years ago
Looks like #PMR - But is it?
Patients referred to rheumatologists for suspected PMR - but is it? And what's the role of imaging to help make the diagnosis?
https://t.co/oinfFXE978 https://t.co/4aAHrYbjZD
Dr. John Cush RheumNow
3 years ago
Could Methotrexate Work in Hand Osteoarthritis?
Lancet reports the results of the METHODS study from Australia where hand osteoarthritis (HOA) patients benefitted from 6 months of methotrexate (MTX) - as long as there was MRI synovitis!
https://t.co/GhVB7WzJLQ https://t.co/Lt0pvm3RCW
Dr. John Cush RheumNow
3 years ago
12.3 million Americans over 50 have osteoporosis; 47 million have osteopenia. W/ OP Fx the risk of repeat Fx is highest in 1st 6 mos, yet 8% of Medicare pts w/ Fx have a diagnostic bone density scan (less in African Americans 5%) https://t.co/2mogEEk3tq https://t.co/9tjwXg0WzZ https://t.co/ruLnjm4kXr
Dr. John Cush RheumNow
3 years ago
Tuesday Nite Rheumatology webinar on the use of steroid-sparing drugs in patients with #PMR.
Featuring Panelists: Drs. David Liew, Robert Spiera, Sarah Mackie, Anisha Dua
Moderator: Dr. Sebastian Sattui
https://t.co/HDXCG1bq2m https://t.co/95vfTnXtNP
Dr. John Cush RheumNow
3 years ago
Tocilizumab Use in #GCA. In 10 yrs, 114 GCA pts started on TCZ after mean 4.5 mos & Rx for 2.3 yrs. GCA Relapse rates:
- before TCZ 0.84/PY
- on TCZ 0.28/PY (P<0.001)
- post TCZ D/C 0.64/PY
52 pts D/C TCZ after 16.8 mos & 27 (52%) relapsed after 8.4 mo https://t.co/D3INiMdC4U https://t.co/aD2rijR6xd
Dr. John Cush RheumNow
3 years ago
Sleep problems in SpA & PsA? Study of 201 pts shows 43% of axSpA and 47% of PsA pts reported sleep problems. In both poor sleep assoc w/ dz activity. In axSpa it signif assoc w/ Dz activity (OR 8.45),biologic use (OR .24), & CRP levels (OR .16) https://t.co/9TEUOODO1P https://t.co/5IhVmOpTCB
What causes polymyalgia rheumatica? It could be said that PMR occurs when trajectories of aging take a wrong turn, but it’s still not clear exactly what it is that causes this to happen. The ideas that follow will doubtless seem, to immunologists, vague and oversimplified; but even a partial picture might still offer a possible framework for clinicians and patients for thinking about treatment and care.
Dr. John Cush RheumNow
3 years ago
Anifrolumab was studied in 7 adolescents w/ resistant #DLE (discoid); given 6 monthly IV doses. All had signif decreases in skin CLASI-A scores (72%) at 1 month (P =.01), sustained at 6-mo F/U. SLEDAI-2K score also decr by 7 pts; 1 had HSV-1 reactivation https://t.co/Nc0IN1Rsao https://t.co/XeAB99YZMF
